Vicarious Surgical Plans to Shut Down Next Week as Cash Runs Out
The Massachusetts surgical robotics company has asked shareholders to vote on dissolving the business on July 21. Investors are unlikely to receive anything back.
Key points
- Vicarious Surgical's board scheduled a shareholder vote on July 21, 2025 to dissolve and liquidate the company.
- The company held just under $3.7 million in cash as of March 31, 2025, against $9 million in total liabilities.
- Vicarious Surgical lost $7.3 million in the first quarter of 2025, following a $50.2 million loss across the full year of 2024.
- CEO Stephen From, President Adam Sachs, and CTO Sammy Khalifa are set to receive a combined minimum of roughly $1.36 million in severance pay.
- The board says ordinary shareholders are unlikely to recover any money.
Vicarious Surgical, a Waltham, Massachusetts company that spent years developing robots to assist with soft-tissue surgery (operations on organs and tissue rather than bone), is preparing to close its doors as soon as next week.
The board of directors has called a special shareholder meeting for July 21. The vote is simple: approve a plan to wind the company down and sell off its assets to pay creditors. Executives and directors together control 55% of the voting power, meaning the outcome is nearly certain.
The board was direct in its warning to investors. "Based upon our current outstanding liabilities, it is unlikely you will receive any distribution," it wrote in a securities filing, a formal document companies must submit to financial regulators.
The numbers tell the story plainly. The company had just under $3.7 million in cash at the end of March. It burned $7.3 million in that quarter alone. It lost $50.2 million across all of 2024 and $63 million the year before that. No buyer stepped forward. No new financing came through.
"We have been unable to secure additional equity, debt or other financing and have been unsuccessful in our efforts to attract a buyer for our business," the company said in the filing.
The Robot Report, which first reported on the shareholder meeting, noted that surgical robotics analyst Steve Bell flagged an upcoming asset auction on LinkedIn, calling it "the end of the road for another interesting soft tissue robot."
What does this mean for the people who worked there?
As of March, Vicarious employed 26 people across research, manufacturing, and administration. Those jobs are gone once the vote passes and operations cease.
Three senior executives will receive severance: CEO Stephen From gets at least $500,000, co-founder and President Adam Sachs at least $541,620, and Chief Technology Officer Sammy Khalifa at least $318,600. All three also receive partial bonus payments and health insurance continuation. The severance contracts were updated in early 2026.
The company's CFO, Sarah Romano, had already resigned to take the same role at a competitor, SS Innovations, effective August 3.
This closure is not a bankruptcy filing. The board chose a state-level assignment process instead, arguing it gives creditors a better shot at recovering money than a federal bankruptcy court would.
For patients and hospitals, the practical impact is limited today since Vicarious Surgical's robot never reached commercial use. The company's failure does, however, reflect how difficult and expensive it is to bring a new surgical robot from idea to operating room. The two dominant players in the space, Intuitive Surgical and Medtronic, spent decades and billions of dollars reaching scale. Smaller entrants have far less room for error.
